Global Research and Evidence Lab 14 August 2024 Dayforce Inc. 2024 Boost amid $500m New Buyback = Buy Non-deal road show offers a glimpse at a Special Software Story We recently hosted Dayforce CEO David Ossip, CFO Jeremy Johnson as well as multiple members from investor relations. We continue to have substantial confidence in our thesis as we believe DAY stock is poised to outperform on cloud revenue remix + improving free cash flow conversion—we believe recent underperformance is mostly due to risk-off se ...

报告行业投资评级 - 报告给予Upwork Inc.的12个月评级为Neutral(中性)[1][7] 报告的核心观点 - 7月Upwork.com的月度独立访客量同比下降11%,与6月持平,但仍处于2年多来的最低水平[9][10] - 管理层已下调全年收入指引,预计下半年GMV将出现明显放缓[10] - 虽然7月数据相对于较弱的预期可能有所好转,但鉴于整体访客量趋势疲弱,目前仍难以判断指引是否过于保守[10] 行业概况 - Upwork是一家在线市场,为企业提供短期和长期项目的自由职业者服务,提供Upwork Basic、Upwork Plus、Upwork Business、Upwork Enterprise和Upwork Payroll等产品[19] 估值与风险 - 我们给予Upwork 11美元的目标价,基于12个月后的预测EBITDA 162百万美元,应用8.5倍EV/EBITDA估值[11][20] - 该估值低于Upwork当前约9.5倍的估值和13倍的一年期预测估值,反映了我们对短期GMV增长乏力的判断[11] - 主要风险包括宏观环境、自由职业市场相对较新、存在替代平台、以及人工智能的影响[21]

报告行业投资评级 Fiverr International Ltd的12个月评级为Neutral(CBE)。[30] 报告的核心观点 1) 根据UBS Evidence Lab的网络流量监测数据,Fiverr.com的月度独立访客量在7月同比下降17%,较6月的15%下降有所加剧。这是连续第二个月呈现恶化趋势,此前自2023年末网络流量同比数据一直在改善。[2][3] 2) 管理层在7月下旬提供的第三季度收入指引已经考虑了上述较弱的趋势。Fiverr表示,6月份看到的放缓将持续到第三季度。分析师和共识预测第三季度GMV同比下降4%,略差于第二季度的3%下降。[3] 3) 分析师认为,7月网络流量的恶化已经反映在当前预测中,但8-9月的走势将很重要。[3] 根据报告目录的总结 网络流量数据 - 7月Fiverr.com的月度独立访客量同比下降17%,较6月的15%下降有所加剧。这是连续第二个月呈现恶化趋势。[2] GMV影响 - 管理层预计第三季度GMV同比下降4%,略差于第二季度的3%下降。[3] - 分析师认为7月网络流量恶化已经反映在当前预测中,但8-9月的走势将很重要。[3] 估值 - 分析师给出27美元的目标价,基于应用9倍NTM EV/EBITDA乘数得出。这一乘数低于Fiverr当前11倍的一年期估值,反映了分析师对近期GMV波动性的担忧。[4][17]

Global Research and Evidence Lab 14 August 2024 Best Buy Co. Inc. A Tough Lap or A Laptop Pop? Expecting an in-line 2Q; QTD comp and category trends will be key We think the most likely case is that BBY reports 2Q EPS inline to slightly better than the consensus EPS estimate of $1.17. That said, we think the market is expecting a total enterprise comp decline slightly below initial guidance for -3% (cons. also -3.0%, our model has a -3.5%). Our checks indicate sales trends improved a bit sequentially from 1 ...

报告行业投资评级 - 报告给予Alibaba集团"买入"评级 [2] 报告的核心观点 Taobao/Tmall业务 - Taobao和Tmall是Alibaba核心业务,在新零售时期经历了激烈竞争,现正在调整业务应对复杂的国内外环境 [25][26][27] - 通过直接平台补贴带动GMV增长,并提升商家预算和运营,从而推动平台的进一步商业化和盈利能力提升 [28][29][30] 国际数字商务业务 - Alibaba的国际电商平台在海外市场仍有广阔的发展空间 [39][40][41][42] - 全托管和半托管模式有助于Alibaba输出中国电商行业的供应链效率和行业经验 [128][129][132][133] 云计算业务 - Alibaba云作为中国云计算市场的领导者,有望从人工智能等新兴需求中获益 [151][152][153][154][155][156][157][158][159][160][161][162][163][164] 菜鸟物流 - 菜鸟物流在国内外电商业务中发挥重要的战略作用,有望随着业务规模扩大而逐步提升盈利能力 [165][166][167][168][173][178][183][184][185][186][187] 本地生活服务 - 饿了么在一些区域实现正向经营周期,具有一定战略价值,但短期内经济意义有限 [192][193][196][197][198][199][200][201][202][203][204][205][206][207][208][209][210] - 高德地图在流量积累方面奠定了良好基础,未来有望通过场景化拓展实现盈利 [211][212][215][216][217][218][219][220][221] 数字媒体娱乐业务 - 虽然历史业绩表现一般,但该业务仍是Alibaba生态系统的重要组成部分,有助于培养核心用户粘性 [226][227][228][229][230][231][232][233][234][235][236][237][238][239][240][241][242][243][244][245][246][247][248][249][250][251][252][253][254][255][256][257]

报告行业投资评级 - 报告给予Cardinal Health Inc.的12个月评级为Buy [4] 报告的核心观点 财务表现 - 2024财年公司营收预计增长10.3%至226.2亿美元 [4] - 2024财年EBIT预计增长16.8%至24.01亿美元 [4] - 2024财年每股收益预计增长27.0%至7.36美元 [4] 业务表现 - 制药分部2025财年收入预计下降4-6%,但剔除Optum业务后将增长15-18% [3] - 专科药品业务2025财年继续保持强劲增长,收入超过360亿美元 [6] - 医疗分部2024财年Q4收入增长2%,利润增长72% [10] - 其他分部2024财年Q4收入增长15%,利润增长11% [11] 现金流和资产负债表 - 2024财年Q4现金余额51亿美元,包括2024年11月到期债务2亿美元和2亿美元定期存款 [12] - 公司之前已发行11.5亿美元新债券以偿还即将到期的债务 [12] 其他 - 与CVS Health合资成立Averon公司,共同开发生物类似药 [8] - 管理层对新客户拓展和现有客户业务扩张表现乐观 [1]

Global Research and Evidence Lab 14 August 2024 First Read Victoria's Secret & Co CEO Appointment as Positive Market Likely to see 2Q EPS Upside and What happened: VSCO pre-announced above-consensus 2Q EPS... VSCO pre-announced 2Q24 results and now anticipates $0.34-$0.39 EPS, above its prior $0.05-$0.20 outlook. We note the Street has been modeling $0.16 Q2 EPS. Within its new Q2 outlook, VSCO expects net sales to be down 1-2% vs. prior down 1-3% y/y. VSCO also raised its Q2 EBIT dollar guidance to $57-$62 ...

Global Research and Evidence Lab 14 August 2024 First Read Progressive Corporation July 2024: PIF Better; underlying loss ratio below consensus How will the stock react? A: We expect a positive reaction to the better-than-expected PIF growth in July while the underlying loss ratio was a little worse than consensus expectations (but beat UBSe). PIF growth accelerated sequentially and was better than expected. PGR should continue to gain market share in the near term as it loosens underwriting restrictions qu ...

Global Research and Evidence Lab 14 August 2024 Madrigal Pharmaceuticals Inc Rezdiffra Formulary Coverage Tracker Rezdiffra coverage substantially improves in July update (50% commercial coverage, consistent w/mgmt commentary). See inside for an overview of the data on coverage and formulary status plan by plan and how Rezdiffra coverage is changing over time. We update our proprietary monthly formulary coverage tracker for MDGL's Rezdiffra using Evidence Lab's US drug formulary monitor (access data here). ...

Global Research and Evidence Lab 14 August 2024 First Read Performance Food Group Company What's The Initial View On 4Q'24 Results? PFGC's 4Q'24 adj EPS $1.45 vs. UBSe $1.35; cons. $1.37; Acquiring Cheney Bros Altogether, we think PFGC's 4Q results reflect its ability to take market share, despite the increasingly challenging macro backdrop. It guided in line to slightly above where we believe market expectations were for adjusted EBITDA for FY'25 (based on our conversations with investors). Still, we belie ...